Mycobacterium tuberculosis

Mycobacterium tuberculosis research compounds act on enzymes and proteins that the tuberculosis bacterium depends on. The genome of the laboratory strain H37Rv, sequenced in 1998, encodes an unusually large set of enzymes for lipid metabolism. Several entries inhibit decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1), an enzyme required for arabinan synthesis in the cell wall. Benzothiazinones, represented here by BTZ043 (BTZ038, BTZ044) Racemate, were shown in 2009 to kill the bacterium by blocking this step. AZ7371 and DprE1-IN-8 are listed as further inhibitors of the same enzyme. PXYC1 and PXYC2 are antagonists of ribosomal protein S1 (RpsA), and MtTMPK-IN-8 inhibits mycobacterial thymidylate kinase. Cefsulodin sodium hydrate is listed as an inhibitor of mycobacterial protein tyrosine phosphatase B (mPTPB), a secreted virulence factor.

Items 51-75 of 77

  • PknB-IN-2
    Cat. No.
    A49369

    PknB-IN-2

    PknB-IN-2 is an inhibitor of Mycobacterium tuberculosis protein kinase B (PknB) with an IC50 value of 12.1 μM. This compound exhibits significant biological activity, making it a valuable tool in the study of tuberculosis pathogenesis and treatment strategies. Research applications include investigations into the role of PknB in bacterial survival and growth, as well as the development of new therapeutic agents targeting tuberculosis.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Tuberculosis inhibitor 7
    Cat. No.
    A49378

    Tuberculosis inhibitor 7

    Tuberculosis Inhibitor 7 (compound 2d) is a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, specifically targeting Mycobacterium tuberculosis and Mycobacterium marinum. This compound demonstrates significant antibacterial activity, exhibiting a minimum inhibitory concentration (MIC90) of 0.63 μM against both strains. It is a valuable tool for research into tuberculosis treatment and for studying mechanisms of drug resistance.

    Out of stock

    All 3 sizes
  • Antituberculosis agent-3
    Cat. No.
    A49390

    Antituberculosis agent-3

    Antituberculosis agent-3 is an effective antituberculosis agent that primarily targets Mycobacterium tuberculosis. It demonstrates significant anti-mycobacterial activity, exhibiting an MIC of 12.5 μg/mL against the M. tuberculosis H37Rv strain. This compound is suitable for research applications focused on tuberculosis treatment and the study of mycobacterial infections.

    Out of stock

    All 3 sizes
  • Mt KARI-IN-1
    Cat. No.
    A49450

    Mt KARI-IN-1

    Mt KARI-IN-1 is a potent inhibitor of Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI) with a Ki value of 3.06 μM. This compound demonstrates significant potential in the study of tuberculosis by effectively disrupting essential metabolic pathways in the bacterium. Its inhibitory activity positions Mt KARI-IN-1 as a valuable tool for research aimed at developing new therapeutic strategies against Mycobacterium tuberculosis.

    Out of stock

    All 3 sizes
  • PptT-IN-3
    Cat. No.
    A49456

    PptT-IN-3

    PptT-IN-3 is a selective inhibitor of phosphopantetheinyl phosphoryl transferase (PptT), exhibiting an IC50 of 3.5 μM. PptT is a vital enzyme involved in the biosynthesis of cellular lipids and virulence factors in Mycobacterium tuberculosis. This compound is a valuable tool for investigating tuberculosis pathogenesis and developing novel therapeutic strategies.

    Out of stock

    All 3 sizes
  • MtTMPK-IN-3
    Cat. No.
    A49462

    MtTMPK-IN-3

    MtTMPK-IN-3 is a potent inhibitor of Mycobacterium tuberculosis thymidylate kinase (MtTMPK), exhibiting an IC50 value of 0.12 μM. It demonstrates effective inhibitory activity against Mtb H37Rv with a minimum inhibitory concentration (MIC) of 12.5 μM. Additionally, MtTMPK-IN-3 displays certain cytotoxic effects in human fibroblast cells (MRC-5) with an EC50 of 12.5 μM. This compound is suitable for research focused on tuberculosis and related therapeutic strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Mtb-IN-9
    Cat. No.
    A49489

    Mtb-IN-9

    Mtb-IN-9 (Compound M1) is a selective inhibitor targeting MtbFadD32 and MtbFadD28, enzymes critical for Mycobacterium tuberculosis survival. This compound effectively reduces Mtb survival within infected macrophages and diminishes the bacterial load and tubercular granulomas in a chronic infection model using BALB/c mice. Mtb-IN-9 holds significant promise for research applications focused on tuberculosis and its underlying mechanisms.

    Out of stock

    All 3 sizes
  • MtTMPK-IN-9
    Cat. No.
    A49560

    MtTMPK-IN-9

    MtTMPK-IN-9 is a selective inhibitor of Mycobacterium tuberculosis thymidylate kinase (MtbTMPK) with an IC50 value of 48 μM. This compound exhibits sub-micromolar antibacterial activity against mycobacterial strains, with minimum inhibitory concentrations (MICs) ranging from 6.25 to 9.4 μM, while demonstrating low cytotoxicity in mammalian cells. MtTMPK-IN-9 is a valuable tool for research into tuberculosis and the development of new therapeutic strategies targeting MtbTMPK.

    Out of stock

    All 3 sizes
  • DQn-1
    Cat. No.
    A49580

    DQn-1

    DQn-1 is a potent antifolate that specifically targets Mycobacterium tuberculosis (Mtb) through the inhibition of dihydrofolate reductase (DHFR) enzyme activity. It exhibits a minimum inhibitory concentration (MIC90) of 0.03 µM against Mtb, while demonstrating IC50 values of 8.7 nM and 7.6 nM for Mtb and human DHFR, respectively. This selectivity highlights its potential for use in research focused on tuberculosis treatment and the mechanisms of antifolate drug action.

    Out of stock

    All 3 sizes
  • Antitubercular agent-30
    Cat. No.
    A49584

    Antitubercular agent-30

    Antitubercular agent-30 is an effective antibacterial agent targeting Mycobacterium tuberculosis, demonstrating an MIC of 50 μg/mL. This compound exhibits minimal cytotoxicity towards murine macrophage cells, with an LD85 of approximately 100 μg/mL. Its selective efficacy makes it a valuable tool for research applications in tuberculosis treatment and drug resistance studies.

    5 mg
    $30.00
    10 mg
    $45.00
    All 6 sizes
  • Polyketide synthase 13-IN-3
    Cat. No.
    A49603

    Polyketide synthase 13-IN-3

    Polyketide synthase 13-IN-3 is a potent inhibitor of polyketide synthase 13, showing a minimum inhibitory concentration (MIC) of 0.0625-0.125 μg/mL against the Mycobacterium tuberculosis strain H37Rv. This compound is valuable for research aimed at understanding the mechanisms of antibiotic resistance and exploring novel therapeutic strategies against tuberculosis. Its selective inhibition may provide insights into polyketide biosynthesis and its implications in microbial pathogenesis.

    5 mg
    $795.00
    All 1 sizes
  • Spectinamide 1599
    Cat. No.
    A49644

    Spectinamide 1599

    Spectinamide 1599 is an anti-infection agent that targets mycobacterial protein synthesis, specifically inhibiting the function of the ribosome. This compound exhibits potent activity against Mycobacterium tuberculosis and is utilized primarily in the development of novel therapies for tuberculosis. Its effectiveness in overcoming drug resistance makes it a valuable tool for research into new anti-tuberculosis treatments.

    25 mg
    $1,275.00
    All 1 sizes
  • (E,Z)-Platanoside
    Cat. No.
    A49657

    (E,Z)-Platanoside

    (E,Z)-Platanoside is a flavonoid glycoside that acts as a potent and highly selective inhibitor of Methicillin-resistant Staphylococcus aureus (MRSA). Demonstrating minimal activity against other strains, including Gram-negative bacteria, intracellular Mycobacterium intracellulare, and various fungi such as Candida albicans and Aspergillus fumigatus, it offers targeted antibacterial effects. This compound is valuable for research applications focused on MRSA infections and the development of new antimicrobial therapies.

    5 mg
    $1,720.00
    All 1 sizes
  • Tuberculosis inhibitor 8
    Cat. No.
    A49692

    Tuberculosis inhibitor 8

    Tuberculosis Inhibitor 8, a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, targets Mycobacterium tuberculosis and demonstrates potent antibacterial activity with a minimum inhibitory concentration (MIC90) of 0.69 μM against both Mycobacterium tuberculosis and Mycobacterium marinum. This compound serves as a valuable tool for research applications focused on the development of novel therapeutic strategies for tuberculosis. Its efficacy against resistant strains makes it significant for studying mycobacterial infections and drug resistance mechanisms.

    Out of stock

    All 3 sizes
  • Antituberculosis agent-1
    Cat. No.
    A49704

    Antituberculosis agent-1

    Antituberculosis agent-1 is a potent antituberculosis compound that targets Mycobacterium tuberculosis. It exhibits a minimum inhibitory concentration (MIC) of 3.84 μg/mL against the H37Rv strain. This agent serves as a valuable tool for research into tuberculosis treatment and understanding the mechanisms of action against resistant strains of M. tuberculosis.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Mtb-IN-2
    Cat. No.
    A49715

    Mtb-IN-2

    Mtb-IN-2 is an antimicrobial agent specifically targeting Mycobacterium tuberculosis (Mtb). Demonstrating significant efficacy, Mtb-IN-2 effectively reduces colony-forming units (CFU) in murine tuberculosis models, providing utility against both drug-sensitive and drug-resistant Mtb H37Rv strains. The compound influences methionine metabolism, while not directly impacting the folate pathway, making it a valuable tool for research into Mtb infection and drug resistance mechanisms.

    1 mg
    $55.00
    5 mg
    $130.00
    All 7 sizes
  • MtTMPK-IN-6
    Cat. No.
    A49760

    MtTMPK-IN-6

    MtTMPK-IN-6 is a selective inhibitor of Mycobacterium tuberculosis thymidylate kinase (MtbTMPK), exhibiting an IC50 value of 29 μM. This compound serves as a valuable tool for investigating the biochemical pathways involved in tuberculosis and may aid in the development of novel therapeutic strategies against M. tuberculosis. Its potency and specificity make it a relevant candidate for further research in the field of infectious diseases.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • MSU-43557
    Cat. No.
    A49822

    MSU-43557

    MSU-43557 is a selective inhibitor of the mycobacterial transporter MmpL3 (MAB_4508), demonstrating potent bactericidal activity against Mycobacterium abscessus. By inhibiting MmpL3, MSU-43557 disrupts the synthesis of trehalose monomycolate, leading to a significant reduction in the viability of biofilm-associated M. abscessus and intracellular forms. This compound exhibits low cytotoxicity in eukaryotic cells and a minimal resistance frequency in M. abscessus strains, making it a valuable tool for research into mycobacterial infections.

    Out of stock

    All 3 sizes
  • Polyketide synthase 13-IN-1
    Cat. No.
    A49837

    Polyketide synthase 13-IN-1

    Polyketide Synthase 13-IN-1 is an inhibitor of polyketide synthase 13, targeting the biosynthetic pathway of polyketides. This compound is significant in research focused on antibiotic development and the synthesis of complex natural products. Its activity provides valuable insights into polyketide metabolism and the potential therapeutic applications of polyketide derivatives.

    5 mg
    $795.00
    All 1 sizes
  • LeuRS-IN-1 hydrochloride
    Cat. No.
    A49844

    LeuRS-IN-1 hydrochloride

    LeuRS-IN-1 hydrochloride is an effective inhibitor of M. tuberculosis leucyl-tRNA synthetase (M.tb LeuRS), showcasing sub-micromolar potency with IC50 and Kd values of 0.06 μM and 0.075 μM, respectively. This compound also inhibits human cytoplasmic leucyl-tRNA synthetase with an IC50 of 38.8 μM and affects protein synthesis in HepG2 cells, demonstrating an EC50 of 19.6 μM. LeuRS-IN-1 hydrochloride is valuable for investigating the mechanisms of antibiotic resistance and for exploring new therapeutic strategies against tuberculosis.

    1 mg
    $1,065.00
    5 mg
    $2,205.00
    All 4 sizes
  • DprE1-IN-10
    Cat. No.
    A49848

    DprE1-IN-10

    DprE1-IN-10 is an inhibitor of Decaprenylphosphoryl-β-D-ribose-2′-epimerase (DprE1), an essential enzyme in the biosynthesis of mycobacterial cell wall components. This compound exhibits strong inhibitory activity against DprE1, making it a valuable tool for researchers studying tuberculosis and exploring potential therapeutic strategies. Its application can lead to significant insights into the mechanisms of mycobacterial infections and the development of antitubercular agents.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Mycobacterium Tuberculosis-IN-2
    Cat. No.
    A49856

    Mycobacterium Tuberculosis-IN-2

    Mycobacterium Tuberculosis-IN-2 is a potent inhibitor specifically targeting Mycobacterium tuberculosis. Demonstrating effective antimicrobial activity with a minimum inhibitory concentration (MIC) ranging from 0.07 to 0.16 μM, this compound serves as a valuable reagent for tuberculosis research, facilitating studies on pathogen resistance and therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • IMB-YH-8
    Cat. No.
    A49938

    IMB-YH-8

    IMB-YH-8 is a selective inhibitor of the serine/threonine protein kinase PknB, demonstrating potent antibacterial activity against Mycobacterium tuberculosis with a minimum inhibitory concentration (MIC) of 0.25 µg/mL. This compound is valuable for researchers investigating tuberculosis, providing insights into the mechanisms of bacterial resistance and potential therapeutic strategies. Its targeted action on PknB enhances its relevance in studies aimed at developing new antimicrobial agents.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Pyrazine-2-carbothioamide
    Cat. No.
    A49962

    Pyrazine-2-carbothioamide

    Pyrazine-2-carbothioamide functions as an antituberculosis agent, exhibiting potent inhibitory activity against Mycobacterium species in vitro. This compound serves as a valuable tool for researchers investigating therapeutic strategies for tuberculosis treatment and exploring the mechanisms of action against Mycobacterium tuberculosis. Its role in antimicrobial research highlights its potential for drug development and efficacy studies.

    250 mg
    $25.00
    500 mg
    $40.00
    All 4 sizes
  • HKI12134085
    Cat. No.
    A50288

    HKI12134085

    HKI12134085 is an orally available antibacterial nitrobenzothiazinone (BTZ) derivative that targets Mycobacterium tuberculosis. It exhibits significant in vivo inhibitory potency in BALB/c mouse models of tuberculosis, demonstrating potential for research applications in the development of novel antituberculosis agents. This compound may serve as a valuable tool for exploring therapeutic strategies against resistant strains of Mycobacterium tuberculosis.

    Out of stock

    All 3 sizes

Items 51-75 of 77

Added to your cart

View Cart Checkout

    Loading...